Latest news with #Nilotinib
News18
6 days ago
- Business
- News18
Cipla Q1 Results: Net Profit Jumps 10.3% YoY To Rs 1,298 Crore, Revenue Up 3.9%
Cipla Share Price: Following Q1 results, shares of Cipla on Friday surge by 3.6% to trade at Rs 1,541.9 apiece on the NSE, as of 2:20 pm. Cipla on Friday reported a 10.3 per cent jump in its consolidated net profit to Rs 1,298 crore for the first quarter ended June 30, 2025. Its revenue from operations in April-June 2025 increased 3.9 per cent to Rs 6,957 crore, compared with Rs 6,694 crore in the year-ago period. The drugmaker's net profit had stood at Rs 1,178 crore in the corresponding quarter last year. Following the results, shares of Cipla on Friday surged by 3.6% to trade at Rs 1,541.9 apiece on the NSE, as of 2:20 pm. Cipla's earnings before interest, taxes, depreciation and amortization (EBITDA) grew 3.6 per cent YoY to Rs 1,778 crore in the quarter under review, while it was reported at Rs 1,716 crore in the year-ago period, while margin was came in at 25.6 per cent YoY. The Mumbai-based drug company reported that its One-India business crossed the Rs 3,000 crore mark for the first time in any first quarter of a financial year, registering a 6% year-on-year growth. In North America, revenue reached $226 million, driven by strong sales of newly launched products like Nano Paclitaxel vials and Nilotinib capsules. The company's Africa operations posted an 11% revenue increase in US dollar terms, while its businesses in Europe and emerging markets grew 8% year-on-year. The company also spent ₹432 crore on research and development during the quarter, which accounted for 6.2% of its total sales, with the focus on new product filings and development. view comments First Published: July 25, 2025, 14:28 IST Disclaimer: Comments reflect users' views, not News18's. Please keep discussions respectful and constructive. Abusive, defamatory, or illegal comments will be removed. News18 may disable any comment at its discretion. By posting, you agree to our Terms of Use and Privacy Policy.
&w=3840&q=100)
Business Standard
23-07-2025
- Business
- Business Standard
Cipla Q1 preview: Net profit may jump up to 4%, revenue by 8% YoY
Cipla Q1FY26 results preview: India's leading pharmaceutical company, Cipla, is expected to report moderate year-on-year (Y-o-Y) growth in both profit and revenue. However, on a quarterly basis, while profit is likely to increase, revenue may see a slight decline. This is due to strong growth in One Africa and EU/Rest of the World regions, while partially offset by muted US sales due to pricing pressure and limited product approvals. The pharma major is scheduled to announce its April-June quarter earnings for the financial year 2025-26 (Q1FY26) on Friday, July 25, 2025. According to brokerages tracked by Business Standard, Cipla may see its average revenue increase by 5.6 per cent year-on-year (Y-o-Y) to ₹7,071 crore as against ₹6,694 crore in the June quarter of FY25. Similarly, on a quarter-on-quarter (Q-o-Q) basis, the topline may grow by 5 per cent compared to ₹6,730 crore in Q4FY25. The pharma major is expected to report an average profit after tax (PAT) of ₹1,208 crore for the June quarter, against ₹1,178 crore in Q1FY25, implying an increase of only 2.6 per cent Y-o-Y for Q1FY26. On a quarterly basis, profits could fall by a marginal 1.12 per cent. The company reported a profit after tax (PAT) of ₹1,222 crore in the March quarter of FY25. According to brokerage forecasts, the company's earnings before interest, tax, depreciation and amortisation (Ebitda) is likely to slightly decrease by 1.3 per cent to ₹1,693 crore in Q1FY25 compared to ₹1,716 crore in the year-ago period. However, on a sequential basis, Ebidta may increase 10 per cent from ₹1,538 crore in the March 2025 quarter. Check List of Q1 results today Here's what the brokerages expect from Cipla Q1FY26 results: Kotak Institutional Equities Despite a slightly modest season, analysts expect Cipla to report a 9 per cent Y-o-Y growth in domestic sales. However, US sales are likely to come in at $221 million, due to slightly higher Lanreotide sales, partially offset by a marginal Quarter-over-Quarter decline in inhaler sales. Kotak also expects strong growth of 16 per cent Y-o-Y in One Africa sales, with South Africa reporting a 15 per cent Y-o-Y growth during the quarter. "In addition, we expect 11 per cent Y-o-Y growth in European Union/Rest of the World sales. Overall, we expect Cipla's Q1FY26 sales to grow 5 per cent Y-o-Y and 5 per cent Q-o-Q," the brokerage said. Motilal Oswal Financial Services The brokerage expects Cipla's US sales to decline 13 per cent Y-o-Y to $219 million for the quarter under review, driven by reduced price of g-Revlimid and limited approvals in Q1FY25. In addition, dosage form (DF) sales are likely to witness moderate growth of 8 per cent Y-o-Y due to weakness in respiratory and anti-diabetes therapies. Analysts are awaiting progress on regulatory measures at the Indore site, an update on the launch of Nilotinib capsules, and the filing of differentiated products with developed markets. Choice Institutional Equities Analysts at Choice Institutional Equities forecast 7.8 per cent Y-o-Y revenue growth, on the back of strong traction in One Africa and moderate growth across other regions. The brokerage expects Ebitda to remain flat due to higher research & development (R&D) spends, with margins contracting 163 bps Y-o-Y. However, PAT is expected to grow 3.7 per cent Y-o-Y. Key monitorables to watch include the management commentary on new biosimilar launches and the anticipated Advair launch. About Cipla Cipla, one of the leading pharmaceutical companies in India, is engaged in the manufacturing, developing, and marketing of a wide range of branded and generic formulations and Active Pharmaceutical Ingredients (APIs). The company's product portfolio includes complex generics as well as drugs in the respiratory, anti-retroviral, urology, cardiology, anti-infective, CNS, and various other key therapeutic segments. Cipla has a presence in India, as well as South Africa, North America, and other key regulated and emerging markets. The company operates 47 manufacturing sites across the globe. It produces 50 dosage forms and over 1,500 products across a wide range of therapeutic categories.
Time of India
30-06-2025
- Business
- Time of India
Analysts betting on these four pharma, hospital stocks due to Indian healthcare sector's strong growth prospects
Pharma segment outlook Hospital segment outlook Sun Pharmaceuticals Gained market share in the domestic formulations segment in Q4 FY25, with 14% year-on-year revenue growth driven by higher volumes and new product launches. Missed Reuters-Refinitiv estimates, with revenue falling short by 3.3% and net profit by 13.3%, primarily due to weaker sales in the US and Rest of the World (RoW) markets. Domestic growth outlook supported by upcoming launches in anti-diabetes and weight management therapies; US growth to come from existing product sales. Plans to invest $100 million in specialty portfolio (dermatology and oncology) for product launches, promotions, and field force expansion. Motilal Oswal remains bullish, citing Sun's push for differentiated offerings in regulated markets to drive future earnings. Reported in-line revenue growth in Q4 FY25, while net profit beat Reuters-Refinitiv estimates by 19.1%, aided by higher other income and lower finance costs. India business drove revenue growth and is expected to remain strong, supported by its innovative portfolio and therapies like respiratory and urology. Recent US approvals for cancer drugs (Abraxane, Nilotinib) and upcoming respiratory launches over the next 12–18 months are expected to stabilise US performance. Management is focused on boosting manufacturing capacity, investing in R&D for differentiated products, and exploring inorganic growth opportunities. According to Antique Stock Broking, Cipla is entering a structural growth phase in the US generics market, driven by continued investment in complex generics, respiratory, and peptide segments. Apollo Hospitals Enterprise An integrated healthcare services provider, the company reported in-line revenue and a 5% net profit beat versus Reuters-Refinitiv estimates in Q4 FY25, supported by higher other income and a lower tax rate; the hospital segment delivered a mixed performance.. ARPOB rose 5% y-o-y driven by higher patient realisation; expected to improve further with better payer mix and rising surgical volumes. Plans to add 3,577 beds over 3-4 years; margin impact from new additions to be offset by cost optimisation. Pharmacy business outlook supported by growing GMV, new store openings, and efficiency measures. Diagnostics segment expected to revive, led by growth in primary and secondary clinics. Motilal Oswal sees positives in bed additions, better productivity at existing facilities, reduced pharmacy losses, and a likely turnaround in diagnostics profitability. Fortis Healthcare Posted in-line revenue and an 11.3% net profit beat in Q4 FY25, driven by higher ARPOB and better occupancy. Hospital revenue grew 14% y-o-y; diagnostics rose 3%. Management expects 14-15% hospital growth in 2025-26 and 24-25% diagnostics margins over 2–3 years. Expansion underway via greenfield projects and acquisitions (Manesar, Jalandhar). Elara Capital raised 2026-27 earnings estimates on strong growth guidance. The healthcare sector—including pharmaceuticals and hospitals— delivered a strong performance in the March 2025 quarter. The pharmaceutical segment benefited from increased demand in chronic therapies within the domestic formulations market, along with steady growth in the US generics business. Meanwhile, the hospitals segment was bolstered by expanded bed capacity and robust growth in average revenue per occupied bed (ARPOB).According to Reuters-Refinitiv data, 129 pharmaceutical companies—including those in biotechnology and life sciences— reported an aggregate revenue growth of 11.5% year-on-year (y-o-y) in the March 2025 quarter. Meanwhile, 26 healthcare providers, including diagnostic firms , recorded a 15.1% year-on-year revenue analysis includes only companies with a market capitalisation above `100 crore. In comparison, Nifty 500 companies posted a lower aggregate revenue growth of 6% healthcare sector performed well in 2024 amid global economic uncertainty driven by geopolitical tensions, trade disruptions, and interest rate volatility. The Nifty Healthcare Index emerged as the second-best performer among the 16 sectoral indices on the National Stock Exchange (NSE) over the past the sector's performance—particularly pharmaceuticals—has moderated in recent months due to concerns over the loss of exclusivity for generic Revlimid (gRevlimid), a cancer drug, which is expected to intensify competition and pressure prices and margins. Additionally, nearterm growth challenges in the domestic formulations segment have weighed on the sector the recent announcement by US President Donald Trump regarding potential tariffs on pharmaceutical imports has dampened investor sentiment. Indian pharmaceutical companies, which earn a significant share of their revenue from US exports, are expected to feel the impact. As a result, the Nifty Pharma Index has become the fourth worst-performing sectoral index on the NSE in 2025 so far, based on data as of 23 June long-term prospects of the pharmaceuticals sector remain intact. A recent Axis Securities report lists strong product pipeline in biosimilars, GLP-1 (class of drugs used to treat diabetes), and peptides (chain of amino acids used to treat diseases), stable margins, and higher contribution from chronic therapies as key growth catalysts for Indian pharmaceutical companies. Moreover, stability in price erosion, differentiated portfolio, and exposure to complex generics is expected to support the US generics concerns remain over the loss of exclusivity for gRevlimid, Indian pharmaceutical companies stand to gain from strong opportunities in the US generics market. The expiry of exclusivity is expected to accelerate generic launches, benefiting manufacturers— particularly Indian to a recent report by Antique Stock Broking, a combination of greater loss-of-exclusivity opportunities, rationalised global competition, and improved regulatory compliance is expected to drive revenue growth for Indian pharmaceutical companies through new product launches and volume gains in existing also see potential in the CDMO (contract development and manufacturing organisation) space. A BNP Paribas report highlights investor feedback suggesting that India stands to benefit as global innovators diversify supply chains away from China. However, concerns persist over high valuations in the segment and limited near-term earnings the hospital segment, factors such as the rise in lifestyle diseases, improving affordability and accessibility driven by higher disposable incomes, a significant demand-supply gap, growing medical tourism, a shift in payer mix due to increased insurance penetration, and bed capacity expansion by private players are expected to drive low healthcare spending in India compared to the world average, rising median age, and a pickup in highgrowth therapies such as cardiac and cancer care—which boost ARPOB and occupancy— are the additional growth catalysts. An IBEF report estimates the Indian hospital market to grow by 8% CAGR between 2022-23 and 2031-32 to reach $193.6 billion. Here are the four stocks (two each from the pharmaceuticals and hospitals segments) with strong analyst TAM growth (%)
Cision Canada
27-05-2025
- Business
- Cision Canada
Apotex launches nilotinib capsules, the first generic version of Tasigna®(1) in the United States, with 180 days of exclusivity
WESTON, Fla., May 27, 2025 /CNW/ - Apotex Corp. today announced the launch of nilotinib capsules, a generic version of Tasigna®, in the United States, with 180 days of exclusivity. Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments. "The launch of nilotinib highlights our commitment to providing affordable, high-quality, critical medications to patients in need," said Christine Baeder, President, Apotex USA. "By offering the first generic version of this important leukemia treatment, we improve access and outcomes for both adult and pediatric patients facing this serious disease." Please refer to the complete prescribing information, patient information leaflet, warnings and precautions, adverse reactions, and contraindications. About Apotex Apotex Corp., headquartered in Weston, Florida, is an affiliate of Apotex Inc. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic and innovative pharmaceutical and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at SOURCE Apotex Inc.
Yahoo
27-05-2025
- Business
- Yahoo
Apotex launches nilotinib capsules, the first generic version of Tasigna®(1) in the United States, with 180 days of exclusivity
WESTON, Fla., May 27, 2025 /CNW/ - Apotex Corp. today announced the launch of nilotinib capsules, a generic version of Tasigna®, in the United States, with 180 days of exclusivity. Nilotinib is a kinase inhibitor indicated to treat certain types of leukemia, including newly diagnosed Philadelphia chromosome positive chronic myeloid leukemia ("Ph+ CML") in chronic phase in adults and children aged 1 year and older. It is also indicated for adults and pediatric patients with chronic or accelerated phase Ph+ CML with resistance or intolerance to prior therapy, demonstrating higher efficacy compared with other available treatments. "The launch of nilotinib highlights our commitment to providing affordable, high-quality, critical medications to patients in need," said Christine Baeder, President, Apotex USA. "By offering the first generic version of this important leukemia treatment, we improve access and outcomes for both adult and pediatric patients facing this serious disease." Please refer to the complete prescribing information, patient information leaflet, warnings and precautions, adverse reactions, and contraindications. About Apotex Apotex Corp., headquartered in Weston, Florida, is an affiliate of Apotex Inc. We improve everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic and innovative pharmaceutical and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico, and India, we are the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions. Learn more about us at _______________________________1 Tasigna® is a registered trademark of Novartis AG View original content to download multimedia: SOURCE Apotex Inc. View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
